Article By:
Trevor Lowenthal
Wednesday, October 8, 2014 12:04 PM EDT
OXiGENE announces that the first patient has been enrolled in the Phase 1b/2 study of fosbretabulin in combination with Votrient(TM) (pazopanib) in patients with recurrent ovarian cancer.
In this article: OXGN